Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 345.1784 USD -0.65% Market Closed
Market Cap: 7.5B USD
Have any thoughts about
Madrigal Pharmaceuticals Inc?
Write Note

Intrinsic Value

MDGL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MDGL stock under the Base Case scenario is 247.4499 USD. Compared to the current market price of 345.1784 USD, Madrigal Pharmaceuticals Inc is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MDGL Intrinsic Value
247.4499 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Madrigal Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MDGL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MDGL?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Madrigal Pharmaceuticals Inc

Provide an overview of the primary business activities
of Madrigal Pharmaceuticals Inc.

What unique competitive advantages
does Madrigal Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Madrigal Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Madrigal Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Madrigal Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Madrigal Pharmaceuticals Inc.

Provide P/S
for Madrigal Pharmaceuticals Inc.

Provide P/E
for Madrigal Pharmaceuticals Inc.

Provide P/OCF
for Madrigal Pharmaceuticals Inc.

Provide P/FCFE
for Madrigal Pharmaceuticals Inc.

Provide P/B
for Madrigal Pharmaceuticals Inc.

Provide EV/S
for Madrigal Pharmaceuticals Inc.

Provide EV/GP
for Madrigal Pharmaceuticals Inc.

Provide EV/EBITDA
for Madrigal Pharmaceuticals Inc.

Provide EV/EBIT
for Madrigal Pharmaceuticals Inc.

Provide EV/OCF
for Madrigal Pharmaceuticals Inc.

Provide EV/FCFF
for Madrigal Pharmaceuticals Inc.

Provide EV/IC
for Madrigal Pharmaceuticals Inc.

Show me price targets
for Madrigal Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Madrigal Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Madrigal Pharmaceuticals Inc?

What are the Net Income projections
for Madrigal Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Madrigal Pharmaceuticals Inc?

What are the EPS projections
for Madrigal Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Madrigal Pharmaceuticals Inc?

What are the EBIT projections
for Madrigal Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Madrigal Pharmaceuticals Inc?

Compare the revenue forecasts
for Madrigal Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Madrigal Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Madrigal Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Madrigal Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Madrigal Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Madrigal Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Madrigal Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Madrigal Pharmaceuticals Inc.

Provide ROE
for Madrigal Pharmaceuticals Inc.

Provide ROA
for Madrigal Pharmaceuticals Inc.

Provide ROIC
for Madrigal Pharmaceuticals Inc.

Provide ROCE
for Madrigal Pharmaceuticals Inc.

Provide Gross Margin
for Madrigal Pharmaceuticals Inc.

Provide Operating Margin
for Madrigal Pharmaceuticals Inc.

Provide Net Margin
for Madrigal Pharmaceuticals Inc.

Provide FCF Margin
for Madrigal Pharmaceuticals Inc.

Show all solvency ratios
for Madrigal Pharmaceuticals Inc.

Provide D/E Ratio
for Madrigal Pharmaceuticals Inc.

Provide D/A Ratio
for Madrigal Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Madrigal Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Madrigal Pharmaceuticals Inc.

Provide Quick Ratio
for Madrigal Pharmaceuticals Inc.

Provide Current Ratio
for Madrigal Pharmaceuticals Inc.

Provide Cash Ratio
for Madrigal Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Madrigal Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Madrigal Pharmaceuticals Inc?

What is the current Free Cash Flow
of Madrigal Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Madrigal Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Madrigal Pharmaceuticals Inc

Current Assets 1.1B
Cash & Short-Term Investments 1.1B
Other Current Assets 14.9m
Non-Current Assets 8.3m
PP&E 3.3m
Intangibles 5m
Current Liabilities 114.3m
Accounts Payable 21.5m
Accrued Liabilities 92.8m
Non-Current Liabilities 117.2m
Long-Term Debt 116.1m
Other Non-Current Liabilities 1m
Efficiency

Earnings Waterfall
Madrigal Pharmaceuticals Inc

Revenue
76.8m USD
Cost of Revenue
-2.8m USD
Gross Profit
74m USD
Operating Expenses
-622.1m USD
Operating Income
-548.1m USD
Other Expenses
29.4m USD
Net Income
-518.7m USD

Free Cash Flow Analysis
Madrigal Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Madrigal Pharmaceuticals celebrated a successful third quarter, generating $62 million in net sales for Rezdiffra, a treatment for NASH, with over 6,800 patients currently prescribed. Coverage now extends to more than 80% of commercial lives, ahead of schedule. The company's team, bolstered by new R&D leadership, is excited about the upcoming European launch set for late 2025 and anticipates significant growth in 2025 due to robust demand and successful drug positioning. Strong early performance metrics suggest that Rezdiffra may become the foundational therapy for NASH, with the enrollment of cirrhosis patients completed in recent trials, positioning them for market leadership.

What is Earnings Call?
Fundamental Scores

MDGL Profitability Score
Profitability Due Diligence

Madrigal Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

40/100
Profitability
Score

Madrigal Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

MDGL Solvency Score
Solvency Due Diligence

Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc

Wall Street analysts forecast MDGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDGL is 376.244 USD with a low forecast of 156.55 USD and a high forecast of 556.5 USD.

Lowest
Price Target
156.55 USD
55% Downside
Average
Price Target
376.244 USD
9% Upside
Highest
Price Target
556.5 USD
61% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MDGL?

Click here to dive deeper.

Dividends

Madrigal Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MDGL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MDGL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

MDGL News

Other Videos

Profile

Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

7.1B USD

Dividend Yield

0%

Description

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in Conshohocken, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2007-02-06. The firm is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The firm's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-Ăź (THR-Ăź) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Contact

PENNSYLVANIA
Conshohocken
200 Barr Harbor Dr Ste 400
+14043809263.0
www.madrigalpharma.com

IPO

2007-02-06

Employees

71

Officers

CEO, President & Director
Mr. William J. Sibold
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
Chief Commercial Officer
Ms. Carole Huntsman
CFO & Senior VP
Ms. Mardi C. Dier
Senior Vice President of Business Planning & Operations
Mr. Mark Underwood
Chief Information Officer
Mr. Ronald Filippo
Show More
Chief Investor Relations Officer
Ms. Tina E. Ventura
Chief Compliance Office & General Counsel
Ms. Shannon Kelley
Chief Human Resources Officer
Mr. Clint Wallace
Senior Vice President of Clinical & Technical Operations
Mr. Edward Chiang
Show Less

See Also

Discover More
What is the Intrinsic Value of one MDGL stock?

The intrinsic value of one MDGL stock under the Base Case scenario is 247.4499 USD.

Is MDGL stock undervalued or overvalued?

Compared to the current market price of 345.1784 USD, Madrigal Pharmaceuticals Inc is Overvalued by 28%.

Back to Top